This ongoing phase II study will evaluate the clinical impact and immunological efficacy of combining a CD4‐help T‐inducer vaccine (universal cancer peptide vaccine, UCPVax) associated with atezolizumab for the treatment of locally advanced or metastatic HPV‐positive cancers (HPV16+). Here, CD4 is linked to cancer.